Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 527-538

  Treede, R D ^a   Wagner, T ^b   Kern, K U ^c   Husstedt, I W ^d   Arendt, G ^e   Birklein, F ^f   Cegla, T ^g   Freynhagen, R ^h   Gockel, H H ⁱ   Heskamp, M L ^j   Jager, H ^k   Joppich, R ^l   Maier, C ^m   Leffler, A ⁿ   Nagelein, H H ^o   Rolke, R ^p   Seddigh, S ^q   Sommer, C ^r   Stander, S ^s   Wasner, G ^t   Baron, R ^t   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

^c Institute of Pain Medicine Pain Practice   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g Krankenhaus St Josef   (Germany)

^h Benedictus Hospital Tutzing   (Germany)

ⁱ Medizinisches Versorgungszentrum   (Germany)

^j Astellas GmbH   (Germany)

^k Diagnostik München   (Germany)

^l Municipal Hospital Koeln Merheim   (Germany)

^m RUHR UNIVERSITY BOCHUM   (Germany)

ⁿ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^o Schmerztherapie Rosenheim   (Germany)

^p UNIVERSITY OF BONN   (Germany)

^q Pain Clinic Mainz   (Germany)

^r UNIVERSITY OF WÜRZBURG   (Germany)

^s UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^t UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

Capsaicin; Capsaicin 8 cutaneous patch; Clinical experience; Consensus workshop; Peripheral neuropathic pain; Responder rate

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCIUM ION; CAPSAICIN; CHEMOKINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOKINE; DULOXETINE; EMLA; GABAPENTIN; LIDOCAINE; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; PREGABALIN; PROSTAGLANDIN; SUBSTANCE P; VANILLOID RECEPTOR 1;

ALLODYNIA; ANTICONVULSANT THERAPY; APPLICATION SITE ERYTHEMA; BACKACHE; BURNING SENSATION; CELL MEMBRANE; CELL ORGANELLE; CELL PROLIFERATION; CERVICOBRACHIAL NEURALGIA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DIAGNOSTIC TEST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GERMANY; HIV ASSOCIATED NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; KERATINOCYTE; MEDIATOR; MONONEUROPATHY; MULTICENTER STUDY (TOPIC); NERVE FIBER; NEUROPATHIC BACK PAIN; NEUROPATHIC PAIN; NEUROPATHY; PAIN ASSESSMENT; PAIN RECEPTOR; PATHOPHYSIOLOGY; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; QUANTITATIVE SENSORY TESTING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN PENETRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; CAPSAICIN; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PAIN MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; SENSORY SYSTEM AGENTS; TIME FACTORS; TRANSDERMAL PATCH;

EID: 84876229378     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.781019     Document Type: Review

References (112)

1. Anand P., Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490-502
2. Nagy I, Santha P, Jancso G, et al. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004;500:351-69
3. Lambert DG. Capsaicin receptor antagonists: a promising new addition to the pain clinic. Br J Anaesth 2009;102:153-5
4. Derry S, Lloyd R, Moore RA, et al. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009;4:CD007393
5. Wallace M, Pappagallo M. Qutenza: a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother 2011;11:15-27
6. Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza) - a review of the evidence. J Pain Palliat Care Pharmacother 2011;25:32-41
7. Qutenza 179mg cutaneous patch - Summary of Product Characteristics (SPC) - (eMC). Available at: http://www.medicines.org.uk/emc/medicine/23156/SPC/ qutenza%20179mg%20cutaneous%20patch/[Last accessed 29 March 2012]
8. Westermann A, Ronnau A-K, Krumova E, et al. Pain-associated mild sensory deficits without hyperalgesia in chronic non-neuropathic pain. Clin J Pain 2011;27:782-9
9. Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27
10. Backonja M, Wallace M, Blonsky E, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7:1106-12
11. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011;12:99-109
12. Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 2012;28(2):101-7
13. Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70:2305-13
14. Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states. Pain 2007;129:256-9
15. Attal N, Bouhassira D, Baron R, et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain 2011;15:441-3
16. Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 2001;92:139-45
17. Petersen K, Rice F, Farhadi M, et al. Natural history of cutaneous innervation following herpes zoster. Pain 2010;150:75-82
18. Rowbotham MC, Yosipovitch G, Connolly MK, et al. Cutaneous innervation density in the allodynic form of postherpetic neuralgia. Neurobiol Dis 1996;3:205-14
19. Rage M, Van A, Knaapen M, et al. Asymptomatic small fiber neuropathy in diabetes mellitus: investigations with intraepidermal nerve fiber density, quantitative sensory testing and laser-evoked potentials. J Neurol 2011;258:1852-64
20. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996;47:1042-8
21. Beiswenger K, Calcutt N, Mizisin A. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 2008;110:351-62
22. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848-55
23. Skopelitis E, Aroni K, Kontos AN, et al. Early detection of subclinical HIV sensory polyneuropathy using intraepidermal nerve fibre density quantification: association with HIV stage and surrogate markers. Int J STD AIDS 2007;18:856-60
24. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998;5:209-27
25. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 2000;16:S12-20
26. Serra J, Sola R, Aleu J, et al. Double and triple spikes in C-nociceptors in neuropathic pain states: an additional peripheral mechanism of hyperalgesia. Pain 2011;152:343-53
27. Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997;17:8003-8
28. Bostock H. Temperature-dependent double spikes in C-nociceptors of neuropathic pain patients (21 February 2012)
29. Orstavik K, Weidner C, Schmidt R, et al. Pathological C-fibres in patients with a chronic painful condition. Brain 2003;126:567-78
30. Schmidt R, Kleggetveit I, Namer B, et al. Double spikes to single electrical stimulation correlates to spontaneous activity of nociceptors in painful neuropathy patients. Pain 2012;153:391-8
31. Anand P. Neurotrophic factors and their receptors in human sensory neuropathies. Prog Brain Res 2004;146:477-92
32. Cheng H, Dauch J, Hayes J, et al. Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes. Neurobiol Dis 2012;45:280-7
33. Griffin JW. The roles of growth factors in painful length dependent axonal neuropathies. In: Campbell JN Emerging Strategies for the Treatment of Neuropathic Pain. Seattle: IASP Press, 2006:271-90
34. Evans L, Andrew D, Robinson P, et al. Increased cutaneous NGF and CGRPlabelled trkA-positive intra-epidermal nerve fibres in rat diabetic skin. Neurosci Lett 2012;506:59-63
35. Jankowski M, Koerber H. Frontiers in neuroscience. Neurotrophic factors and nociceptor sensitization. Translational pain research: from mouse to man. In: Kruger L, Light AR (eds). Frontiers in Neuroscience. Boca Raton, FL: CRC Press; 2010
36. Quarta S, Vogl C, Constantin C, et al. Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro. Mol Pain 2011;7:73
37. Okamoto K, Martin DP, Schmelzer JD, et al. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol 2001;169:386-91
38. Opree A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2000;20:6289-93
39. Li D, Ren Y, Xu X, et al. Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin generelated peptide driven by dorsal root reflexes. J Pain 2008;9:1155-68
40. Campbell J, Meyer R. Mechanisms of neuropathic pain. Neuron 2006;52: 77-92
41. Wang T, Molliver D, Jing X, et al. Phenotypic switching of nonpeptidergic cutaneous sensory neurons following peripheral nerve injury. PLoS One 2011;6:e28908
42. Zhu Y, Colak T, Shenoy M, et al. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology 2011;141:370-7
43. Schumacher M. Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Pain Pract 2010;10:185-200
44. Bowles W, Sabino M, Harding-Rose C, et al. Chronic nerve growth factor administration increases the peripheral exocytotic activity of capsaicin-sensitive cutaneous neurons. Neurosci Lett 2006;403:305-8
45. Ji R-R, Samad T, Jin S-X, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68
46. Schumacher M, Eilers H. TRPV1 splice variants: structure and function. Front Biosci 2010;15:872-82
47. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24
48. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-212
49. Gallego-Sandin S, Rodriguez-Garcia A, Alonso M, Garcia-Sancho J. The endoplasmic reticulum of dorsal root ganglion neurons contains functional TRPV1 channels. J Biol Chem 2009;284:32591-601
50. Rosenbaum T, Simon S. Frontiers in Neuroscience. TRPV1 receptors and signal transduction. TRP ion channel function in sensory transduction and cellular signaling cascades. In: Liedtke WB, Heller S (eds). Frontiers in Neuroscience. Boca Raton (FL): CRC Press; 2007
51. Chung M-K, Guler A, Caterina M. TRPV1 shows dynamic ionic selectivity during agonist stimulation. Nat Neurosci 2008;11:555-64
52. Pingle SC, Matta JA, Ahern GP. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol 2007;179:155-171
53. Cortright D, Szallasi A. TRP channels and pain. Curr Pharm Des 2009;15:1736-49
54. Ma W, Quirion R. Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain. Expert Opin Ther Targets 2007;11:307-20
55. Planells-Cases R, Garcia-Sanz N, Morenilla-Palao C, et al. Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia. Pflugers Arch 2005;451:151-9
56. Jain A, Bronneke S, Kolbe L, et al. TRP-channel-specific cutaneous eicosanoid release patterns. Pain 2011;152:2765-72
57. Goswami C, Schmidt H, Hucho F. TRPV1 at nerve endings regulates growth cone morphology and movement through cytoskeleton reorganization. FEBS J 2007;274:760-72
58. Xu H, Tian W, Fu Y, et al. Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. Am J Physiol Renal Physiol 2007;293:F1865-76
59. Xu X, Wang P, Zou X, et al. The effects of sympathetic outflow on upregulation of vanilloid receptors TRPV(1) in primary afferent neurons evoked by intradermal capsaicin. Exp Neurol 2010;222:93-107
60. Binder A, May D, Baron R, et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One 2011;6:e17387
61. Stander S, Moormann C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004;13:129-39
62. Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol 2012;166(2):510-21
63. Denda M, Tsutsumi M. Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes. Adv Exp Med Biol 2011;704:847-60
64. Denda S, Denda M, Inoue K, et al. Glycolic acid induces keratinocyte proliferation in a skin equivalent model via TRPV1 activation. J Dermatol Sci 2010; 57:108-13
65. Moran M, McAlexander M, Biro T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011;10:601-20
66. Radtke C, Sinis N, Sauter M, et al. TRPV channel expression in human skin and possible role in thermally induced cell death. J Burn Care Res 2011; 32:150-9
67. Schmelz M. Neuronal sensitivity of the skin. Eur J Dermatol 2011;21(Suppl 2):43-7
68. Huang S, Lee H, Chung MK, et al. Overexpressed transient receptor potential vanilloid 3 ion channels in skin keratinocytes modulate pain sensitivity via prostaglandin E2. J Neurosci 2008;28:13727-37
69. Aubdool A, Brain S. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc 2011;15:33-9
70. Stander S, Schneider S, Weishaupt C, et al. Putative neuronal mechanisms of sensitive skin. Exp Dermatol 2009;18:417-23
71. Pecze L, Szabo K, Szell M, et al. Human keratinocytes are vanilloid resistant. PLoS One 2008;3:e3419
72. Szolcsanyi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides 2004;38:377-84
73. Spitzer MJS, Reeh PW, Sauer SK. Mechanisms of potassium- and capsaicininduced axonal calcitonin gene-related peptide release: involvement of L- and T-type calcium channels and TRPV1 but not sodium channels. Neuroscience 2008;151:836-42
74. Han P, McDonald H, Bianchi B, et al. Capsaicin causes protein synthesis inhibition and microtubule disassembly through TRPV1 activities both on the plasma membrane and intracellular membranes. Biochem Pharmacol 2007;73:1635-45
75. Shimomura Y, Kawada T, Suzuki M. Capsaicin and its analogs inhibit the activity of NADH-coenzyme Q oxidoreductase of the mitochondrial respiratory chain. Arch Biochem Biophys 1989;270:573-7
76. Simone DA, Nolano M, Johnson T, et al. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 1998;18:8947-59
77. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999;81:135-45
78. Gibbons CH, Wang N, Freeman R. Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol 2010;68:888-98
79. Kennedy WR, Vanhove GF, Lu S-P, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010;11:579-87
80. Ragé M, van Acker N, Facer P, et al. The time course of CO2 laser-evoked responses and of skin nerve fibre markers after topical capsaicin in human volunteers. Clin Neurophysiol 2010;121:1256-66
81. Magerl W, Fuchs PN, Meyer RA, et al. Roles of capsaicin-insensitive nociceptors in cutaneous pain and secondary hyperalgesia. Brain 2001;124: 1754-64
82. Kasting GB. Kinetics of finite dose absorption through skin 1. Vanillylnonanamide. J Pharm Sci 2001;90:202-12
83. Babbar S, Chanda S, Bley K, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit 2009;31:502-10
84. Babbar S, Chanda S, Bley K. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 2010;40:807-16
85. Reilly C, Yost G. Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev 2006;38:685-706
86. Chanda S, Bashir M, Babbar S, et al. In vitro hepatic and skin metabolism of capsaicin. Drug Metab Dispos 2008;36:670-5
87. England J, Wagner T, Kern K-U, et al. The capsaicin 8% patch for peripheral neuropathic pain. Br J Nurs 2011;20:926-31
88. Backonja MM, Malan TP, Vanhove GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 2010;11:600-8
89. Webster LR, Malan TP, Tuchman MM, et al. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 2010;11:972-82
90. Clifford DB, Simpson, DM Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2011;59(2):126-33
91. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
92. Kern, U. Hochdosiertes Capsaicin-Pflaster in der Behandlung peripherer neuropathischer Schmerzen. Ein Erfahrungsbericht mit 58 Patienten. Psychopharmakotherapie 2012;19:72-5
93. Wagner T, Roth-Daniek A, Sell A, et al. Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from 'real-world' clinical experience. Pain Management 2012;2:239-50
94. Baron R, Binder A. How neuropathic is sciatica? The mixed pain concept. Orthopade 2004;33:568-75
95. Moore RA, Derry S, McQuay HJ, et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149:173-6
96. Dworkin R, Turk D, McDermott M, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009;146:238-44
97. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94
98. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010;149:177-93
99. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006;123:231-43
100. Geber C, Klein T, Azad S, et al. Test-retest and interobserver reliability of quantitative sensory testing according to the protocol of the German Research Network on Neuropathic Pain (DFNS): a multi-centre study. Pain 2011;152:548-56
101. Backonja M-M, Walk D, Edwards R, et al. Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain 2009;25:641-7
102. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108:248-57
103. Sommer C, Richter H, Rogausch J, et al. A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol 2011;11:104
104. Freynhagen R, Baron R, Gockel U, Tolle T. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
105. Baron R, Tolle T, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 2009;146: 34-40
106. Mahn F, Hullemann P, Gockel J, et al. Sensory symptom profiles and comorbidities in painful radiculopathy. PLoS One 2011;6:e18018
107. Tampin B, Briffa NK, Slater H. Self-reported sensory descriptors are associated with quantitative sensory testing parameters in patients with cervical radiculopathy, but not in patients with fibromyalgia. Eur J Pain 2012
108. Maier C, Baron R, Tolle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010;150:439-50
109. Mythili A, Kumar K, Subrahmanyam KA, et al. A comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy. Int J Diabetes Dev Ctries 2010;30:43-8
110. Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11:999-1005
111. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73:638-52
112. Baumgartner U, Greffrath W, Treede R-D. Contact heat and cold, mechanical, electrical and chemical stimuli to elicit small fiber-evoked potentials: merits and limitations for basic science and clinical use. Neurophysiol Clin 2012;42:267-80